Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team

San Diego, California, UNITED STATES

SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for the treatment of allergic reactions (Type I) including anaphylaxis.

Gus Fernandez, Pharm.D., MBA, has joined Adamis as Vice President of Commercial Operations. In this role, he will work closely with other senior management members to direct all aspects of commercial sales. Most recently, he served as National Business Director for inVentiv Health Commercial Services where he formed, recruited and retained sales teams. Prior to inVentiv, he was VP of Commercial Development and Operations for Avanir Pharmaceuticals where he was responsible for new product planning and commercial operations. Before Avanir, he held several managing roles over a six year period for Dura Pharmaceuticals including Director of Sales Operations. At Dura, he directed a staff of thirteen which supported over 400 sales professionals. He also spent six years as a sales representative for Eli Lilly & Company.

Louis J. Fayant, MBA, has joined Adamis as Director of Account Management. For several years, he was Director of Managed Care for Dey L.P. which became a subsidiary of Mylan. There, he oversaw all operations of Dey's US Managed Care Department which impacted over 50% of the company's branded sales, including the EpiPen®. Prior to Dey L.P., he served as Director of Pharmacy Benefit Management for Dura Pharmaceuticals for four years. Before Dura, he spent ten years with Forest Laboratories as a Division Sales Manager and Regional Managed Care Executive growing its formulary access with commercial payers. In addition to his extensive work with EpiPen®, he has also spent over 20 years working in the Asthma/COPD spaces in various capacities.

David J. DeLay has also joined Adamis as Senior National Accounts Manager – Alternative Markets. Most recently, he was Director of National Accounts for Halozyme Therapeutics. Prior to Halozyme, he served as Director of National Accounts for Verus Pharmaceuticals where he established TwinJect® stocking in wholesale and retail facilities while securing reimbursement with payers nationwide. For more than a decade, he also served in various account management leadership roles for Vertex Pharmaceuticals, Biovail Pharmaceuticals and Forest Pharmaceuticals.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "We have strengthened our commercial sales team by adding these talented individuals who will continue to prepare our company for our first commercial product launch. Louis Fayant and David DeLay have worked closely with other products within the anaphylaxis treatment space and bring a wealth of knowledge for growing sales in the managed accounts markets. Gus Fernandez has managed sales operations for highly successful pharmaceutical companies and has invaluable experience with pre-launch planning and on-market commercialization. Their collective expertise and abilities to build and lead top-performing commercial teams will be a great asset to Adamis as we continue towards commercialization of our products."

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, APC-2000 for the treatment of bronchospasms, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.


Contact Data